A61K 40/4266
Carcinoembryonic antigen [cea]
Official title: {Carcinoembryonic antigen [CEA]}
A61K40/4266 (Carcinoembryonic antigen [cea]) appears on 105 US grants and 206 published applications in this corpus.
Search patents in A61K- Granted patents
- 105
- Published applications
- 206
- Assignees
- 131
- Inventors
- 388
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 1 |
| 2003 | 2 | 2 |
| 2004 | 0 | 7 |
| 2005 | 2 | 6 |
| 2006 | 0 | 0 |
| 2007 | 1 | 4 |
| 2008 | 3 | 5 |
| 2009 | 0 | 3 |
| 2010 | 4 | 1 |
| 2011 | 4 | 6 |
| 2012 | 0 | 4 |
| 2013 | 1 | 3 |
| 2014 | 3 | 3 |
| 2015 | 3 | 4 |
| 2016 | 2 | 7 |
| 2017 | 4 | 6 |
| 2018 | 6 | 8 |
| 2019 | 4 | 9 |
| 2020 | 6 | 19 |
| 2021 | 5 | 18 |
| 2022 | 17 | 21 |
| 2023 | 9 | 27 |
| 2024 | 6 | 22 |
| 2025 | 12 | 8 |
| 2026 | 8 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production16 Jun 2026US 12,655,391 B2Gene Solutions Joint Stock Company
- All-in one vector for CAR and therapeutic effector molecule26 May 2026US 12,637,694 B2Medizinische Hochschule Hannover
- Recombinant promoter system specifically inducing high level of gene expression after t cell activation9 Jul 2026US 2026/0191906 A1Xuzhou Medical University
- Compositions and methods for treating ceacam positive cancers2 Jul 2026US 2026/0184763 A1A2 Biotherapeutics, Inc.
- Methods and compositions for cell-surface co-localization of chimeric proteins18 Jun 2026US 2026/0166083 A1Senti Biosciences, Inc.
- Armed chimeric receptors and methods of use thereof28 May 2026US 2026/0144818 A1Senti Biosciences, Inc.
- haNK Cetuximab Combinations And Methods28 May 2026US 2026/0144868 A1NantCell, Inc.
Most cited
By later US patents
- Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule63US 6,045,802 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 2000
- HLA class I A2 tumor associated antigen peptides and vaccine compositions58US 6,602,510 B1Epimmune Inc. · 2003
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule52US 6,548,068 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2003
- Noninvasive genetic immunization, expression products therefrom and uses thereof50US 6,348,450 B1The UAB Research Foundation · 2002